University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.

Ackermans & van Haaren fund Sofinim returned for a $20.6m round that will fund the cancer-analysis software provider's expansion and product development.

CCSL will use the proceeds from the Marubeni and Chevron Technology Ventures-backed round to advance its carbon capture project pipeline.

Karolinska Development banked a $32.4m annual profit after the successful IPO of Aprea Therapeutics, amid improvements to its operational finances.

ResMed joined another medical device producer, Cochlear, in a $27.2m round that will help Nyxoah get regulatory clearance for its sleep apnoea system in the US.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Parkwalk Advisors is lining up investment to fund series C rounds for 10 of its portfolio companies, including spinouts of the universities of Oxford and Cambridge.

Braavos Capital has emerged as the largest shareholder in OSI, having picked up stakes from IP Group, Invesco and Woodford Investment Management.

The fourth fund of ULB’s venture unit now stands at $41.2m having extended its investment purview to include spinouts in Quebec.